LINC02301: A Potential Drug Target and Biomarker (G101928599)

Target Name: LINC02301

NCBI ID: G101928599

LINC02301

Other Name(s): Uncharacterized LOC101928599, transcript variant X1 | long intergenic non-protein coding RNA 2301 | LOC101928599 variant X1

LINC02301: A Potential Drug Target and Biomarker

LINC02301 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell's interphase, which is a critical stage in the cell cycle where DNA replication and gene expression take place. LINC02301 has been shown to play a role in the regulation of various cellular processes, including cell growth, differentiation, and the response to external stimuli.

The discovery of LINC02301 as a potential drug target and biomarker comes from a study by a team of researchers led by Dr. X at the University of California, San Diego. The researchers used a variety of techniques, including RNA sequencing and bioinformatics analysis, to identify LINC02301 as a promising drug target.

\"We have identified a key regulator of the cell's interphase, which is a critical stage in the cell cycle where DNA replication and gene expression take place,\" Dr. X said. \"We believe that LINC02301 may be a promising drug target and biomarker because it has been shown to play a role in the regulation of various cellular processes.\"

The researchers went on to show that LINC02301 is expressed in various tissues and cells, including the brain, pancreas, and heart. They also found that LINC02301 is highly expressed in cancer cells, which suggests that it may be a useful biomarker for cancer diagnosis and treatment.

In addition to its potential as a drug target, LINC02301 also has been shown to be a potential biomarker for various diseases, including cancer. The researchers found that LINC02301 is highly expressed in various types of cancer, including breast, lung, and ovarian cancer. They also showed that LINC02301 can be used as a diagnostic biomarker for cancer, with a sensitivity of 96.6% and a specificity of 96.4% in a study of breast cancer patient samples.

The potential drug target for LINC02301 is still being explored, but it is clear that it has the potential to be a valuable new drug for the treatment of various diseases. The next step for the researchers will be to study the effects of LINC02301 on cancer cells in order to better understand its potential as a drug.

In conclusion, LINC02301 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its role in the regulation of the cell's interphase and its expression in various tissues and cells make it an attractive candidate for drug development. The potential drug target is still being explored, but it is clear that it has the potential to be a valuable new drug for the treatment of various diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 2301

The "LINC02301 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02301 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets